The influence of psychotropic drugs on cerebral cell death: Female neurovulnerability to antipsychotics

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 145-149

  Bonelli, Raphael M ^a   Hofmann, Peter ^a   Aschoff, Andreas ^b   Niederwieser, Gerald ^c   Heuberger, Clemens ^d   Jirikowski, Gustaf ^b   Kapfhammer, Hans Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Hospital BHB Eggenberg   (Austria)

^d GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Alzheimer's disease; Antipsychotic drugs; Apoptosis; Neurotoxicity; Tardive dyskinesia; Tissue transglutaminase

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRAMADOL; TRANQUILIZER;

ADULT; AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN CELL; CELL DEATH; CELL VIABILITY; CEREBROSPINAL FLUID ANALYSIS; ELDERLY CARE; FEMALE; HUMAN; HUNTINGTON CHOREA; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SIDE EFFECT; TARDIVE DYSKINESIA;

AGED; AGING; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; TRANSGLUTAMINASES;

EID: 17644366113     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00004     Document Type: Article

References (25)

1. Andreassen OA, Jorgensen HA (2000). Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61:525-541.
2. Bailey CD, Graham RM, Nanda N, Davies PJ, Johnson GV (2004). Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Mol Cell Neurosci 25:493-503.
3. Behl C, Rupprecht R, Skutella T, Holsboer F (1995). Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport 7:360-364.
4. Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G (2002). Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. Neurobiol Dis 11:106-110.
5. Cadet JL, Kahler LA (1994). Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18:457-467.
6. Casey DE (2004). Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 (suppl 9):25-28.
7. Cummings JL (2004). Alzheimer's disease. N Engl J Med 351:56-67.
8. Dalgalarrondo P, Gattaz WF (1994). Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 244:272-277.
9. Galili-Mosberg R, Gil-Ad I, Weizman A, Melamed E, Offen D (2000). Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J Neural Transm 107:479-490.
10. Gil-Ad I, Shtaif B, Shiloh R, Weizman A (2001). Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 21:705-716.
11. Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML, Powers RE (1997). Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751:323-329.
12. Lesort M, Tucholski J, Miller ML, Johnson GV (2000). Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 61: 439-463.
13. Mion CC, Andreasen NC, Arndt S, Swayze VW II, Cohen GA (1991). MRI abnormalities in tardive dyskinesia. Psychiatry Res 40:157-166.
14. Noh JS, Kang HJ, Kim EY, Sohn S, Chung YK, Kim SU, Gwag BJ (2000). Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J Neurochem 75:2327-2334.
15. Nussbaum RL, Ellis CE (2003). Alzheimer's disease and Parkinson's disease. N Engl J Med 348:1356-1364.
16. Oliverio S, Amendola A, Rodolfo C, Spinedi A, Piacentini M (1999). Inhibition of 'tissue' transglutaminase increases cell survival by preventing apoptosis. J Biol Chem 274:34123-34128.
17. Patt RB, Proper G, Reddy S (1994). The neuroleptics as adjuvant analgesics. J Pain Symptom Manage 9:446-453.
18. Post A, Rucker M, Ohl F, Uhr M, Holsboer F, Almeida OF, Michaelidis TM (2002). Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 26:397-407.
19. Sunderland T, Cohen BM (1987). Blood to brain distribution of neuroleptics. Psychiatry Res 20:299-305.
20. Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T (2004). Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 111:667-681.
21. Volokhina EB, Hulshof R, Haanen C, Vermes I (2003). Tissue transglutaminase mRNA expression in apoptotic cell death. Apoptosis 8:673-679.
22. Yassa R, Jeste DV (1992). Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18:701-715.
23. Yassa R, Nastase C, Dupont D, Thibeau M (1992). Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 149:1206-1211.
24. Zitman FG, Linssen AC, Edelbroek PM, Van Kempen GM (1991). Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? Pain 47:25-30.
25. Zitman FG, Pennings TM, Raes DC, Hekster YA (1994). Neuroleptic drug use in nonpsychiatric departments of a Dutch university hospital. Gen Hosp Psychiatry 16:32-37.